Three books. One argument.
Science creates possibility. The system around it decides what becomes usable, fundable, and durable — and what quietly stalls.
DIAGNOSTICS · BIOPHARMA
01 / THE BOOKS
Frontier and Threshold form The Diagnostics Operating System, a two-book series tracing how a diagnostic category is made and then mastered. Beyond the Molecule carries the same lens into biopharma. Each book stands alone — none assumes you have read the others.
China and the West in the New Race to Build Diagnostic Categories
A field guide to what happens before a category hardens — when strong science stalls in translation at workflow, evidence, reimbursement, trust, company form, and the ownership path it requires next. Frontier asks which emerging categories are real, which are premature, and what it takes to build something the world can carry.
Who turns a discovery into a category?
China’s Rise and the New Operating System of Diagnostics
Once legitimacy is settled, buyers stop paying for novelty and start paying for continuity: supply, service, software governance, workflow fit, and procurement credibility. The real product is no longer the instrument — it is the operating system that carries it. Threshold is a field guide to competing when the ability to run matters more than the ability to launch.
Who can carry the category at scale?
Frontier begins where a category is still soft and being decided. Threshold begins where its legitimacy is settled and the contest turns to who can carry it. Read as a pair, they trace the full life of a diagnostic category — how it is made, and then mastered.
The same lens, applied to a different field.
How Therapeutic Categories Form, Who Controls Them, and How They Are Disrupted
A molecule can be approved, prescribed, and genuinely beneficial — and still not constitute a formed category. Beyond the Molecule carries the category lens into biopharma, tracing the sequence of proofs — biological, modality, delivery, translational, manufacturing, clinical — that decide whether biology becomes a therapeutic category the world can carry.
Where does control move after invention?
02 / THE FRAMEWORK
A technology can be excellent and still fail. These books follow the larger system that determines whether invention acquires a usable form, durable legitimacy, and a defensible position.
Form
Discovery must cross the translation relay: evidence, workflow, trust, economics, and ownership.
Carry
Once legitimacy is settled, continuity and integration matter more than novelty alone.
Control
Control moves to infrastructure, evidence, delivery, access, standards, and the ability to renew.
“Was the technology impressive, or could the system around it make it real?”
— Preface, Frontier
03 / KEY THEMES
How a scientific possibility becomes a recognized field of action.
Why strong technology stalls at the handoffs between proof, workflow, trust, and economics.
The capabilities around a product that make it deployable, governable, and durable.
How advantage migrates from invention to infrastructure, evidence, access, and renewal.
How two systems increasingly shape categories through different operating logics — rather than along one shared path.
Where to lead, partner, defend, harvest, or exit as a category changes state.
WHO THESE BOOKS ARE FOR
Founders, executives, investors, strategists, operators, and technical leaders who build, fund, evaluate, or compete in diagnostics, life-science tools, healthcare platforms, and biopharma.